US 2024/0180932 A1Published application

Substituted resorcylic acid compounds in the management of ageing and related disorders

AssigneeSociete des Produits Nestle S.A.

InventorsMATTHEW SANDERS, DENIS MARCEL BARRON, OLIVIER CICLET, MARTINE NARANJO PINTA, KAMILA MULLER, VINCENZO SORRENTINO, ROBIN WILLOWS

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention relates to composition comprising at least a compound having general formula (I) for use in (i) increasing resistance to age-related pathologies, (ii) improving a physiological state or disorder related to cell ageing, (iii) improving a physiological state linked to metabolic fatigue in one or more cells, (iv) increasing mitochondrial energy in one or more cells, (v) increasing antioxidant capacity, reducing oxidative stress and/or enhancing mitochondrial function, (vi) improving mobility and/or (vii) improving healthspan and/or lifespan in an individual. The present invention also relates to a compound having general formula I for use as an autophagy inducer.

Claims22

Dependent claims

A method for (i) increasing resistance to age-related pathologies, (ii) improving a physiological state or disorder related to cell ageing, (iii) improving a physiological state linked to metabolic fatigue in one or more cells, (iv) increasing mitochondrial energy in one or more cells, (v) increasing antioxidant capacity, reducing oxidative stress and/or enhancing mitochondrial function, (vi) improving mobility and/or (vii) improving healthspan and/or lifespan in an individual comprising administering a composition comprising a compound having the general formula I, in an effective amount to the individual

wherein R1 and R3 are each independently selected from the group consisting of OH;
OCH3;
O-aliphatic saturated or unsaturated acyl, O-glycoside;
acylated O-glycoside;
sulfated O-glycoside;
or a sulfate,
R2, R4, and R5 are each independently selected from the group consisting of H, OH;
OCH3;
O-glycoside;
C-glycoside;
acylated O-glycoside;
acylated C-glycoside;
sulfated O-glycoside;
sulfated C-glycoside;
a halogen;
a primary, secondary, or tertiary alcohol;
a ketone;
an aldehyde;
an ester;
a primary, secondary, or tertiary amine;
a primary or secondary amide;
a cyano;
a nitro;
a sulfonate;
a sulfate;
substituted and branched C1 to C20 alkyl;
substituted and branched, C2 to C20 alkenyl;
substituted and branched, C4 to C20 polyalkenyl;
substituted and branched C2 to C20 alkynyl, and substituted and branched C4 to C20 polyalkynyl,
and a derivative or analogue thereof, a OCH3 group can cyclize with a neighboring OH group to form a methylene dioxy bridge.

27 more elements

A method for delaying off-set of metabolic decline, maintaining muscle mass and/or muscle function, decreasing oxidative stress, maintaining immune function and/or maintaining cognitive function in a healthy older adult comprising administering a composition comprising at least a compound having the general formula I, in a therapeutically effective amount to the adult,

wherein R1 and R3 are each independently selected from the group consisting of OH;
OCH3;
O-aliphatic saturated or unsaturated acyl, O-glycoside;
acylated O-glycoside;
sulfated O-glycoside;
and a sulfate,
R2, R4, and R5 are each independently selected from the group consisting of H, OH;
OCH3;
O-glycoside;
C-glycoside;
acylated O-glycoside;
acylated C-glycoside;
sulfated O-glycoside;
sulfated C-glycoside;
a halogen;
a primary, secondary, or tertiary alcohol;
a ketone;
an aldehyde;
an ester;
a primary, secondary, or tertiary amine;
a primary or secondary amide;
a cyano;
a nitro;
a sulfonate;
a sulfate;
substituted and branched C1 to C20 alkyl;
substituted and branched, C2 to C20 alkenyl;
substituted and branched, C4 to C20 polyalkenyl;
substituted and branched C2 to C20 alkynyl, or substituted and branched C4 to C20 polyalkynyl.
and a derivative or analogue thereof, a OCH3 group can cyclize with a neighboring OH group to form a methylene dioxy bridge.

27 more elements

A method for inducing autophagy comprising administering a compound having the general formula I,

wherein R1 and R3 are each independently selected from the group consisting of OH;
OCH3;
O-aliphatic saturated or unsaturated acyl, O-glycoside;
acylated O-glycoside;
sulfated O-glycoside;
and a sulfate,
R2, R4, and R5 are each independently selected from the group consisting of H, OH;
OCH3;
O-glycoside;
C-glycoside;
acylated O-glycoside;
acylated C-glycoside;
sulfated O-glycoside;
sulfated C-glycoside;
a halogen;
a primary, secondary, or tertiary alcohol;
a ketone;
an aldehyde;
an ester;
a primary, secondary, or tertiary amine;
a primary or secondary amide;
a cyano;
a nitro;
a sulfonate;
a sulfate;
substituted and branched C1 to C20 alkyl;
substituted and branched, C2 to C20 alkenyl;
substituted and branched, C4 to C20 polyalkenyl;
substituted and branched C2 to C20 alkynyl, substituted and branched C4 to C20 polyalkynyl,
and a derivative or analogue thereof, a OCH3 group can cyclize with a neighboring OH group to form a methylene dioxy bridge.

27 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/552,055Filed 25 Mar 2022
Priority: EP 21165056.925 Mar 2021
Published: 6 Jun 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 31/203
Having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids: retinoic acids ; Salts thereof
A61K 31/658
Medicinal preparations containing organic active ingredients: o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or…
A61P 35/00
Antineoplastic agents
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00